Cobenfy is a new schizophrenia medication approved by the FDA in September 2024 that targets acetylcholine receptors, unlike older anti-psychotic drugs that primarily target dopamine. This novel mechanism is designed to improve positive and negative symptoms while minimizing side effects like motor problems and sedation. It is a combination of xanomeline and trospium chloride, which also helps improve cognitive and negative symptoms, and was developed with contributions from researchers at Monash University.
Discuss in this thread your experiences with Cobenfy.
Discuss in this thread your experiences with Cobenfy.